Novel Prognostic Gene Mutations Identified in Chronic Lymphocytic Leukemia and Their Impact on Clinical Practice

Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia

“…Consequently, the presence of the SF3B1 mutations in the CLL cells is concerned with less favorable prognosis. Patients with SF3B1 mutations were characterized by significantly shorter time to treatment, short PFS after treatment and also low OS rate [65,73]. Moreover, SF3B1 mutations are associated with chemoresistance to alkylating agents and fludarabine therapy [71,73].…”

“…Patients with SF3B1 mutations were characterized by significantly shorter time to treatment, short PFS after treatment and also low OS rate [65,73]. Moreover, SF3B1 mutations are associated with chemoresistance to alkylating agents and fludarabine therapy [71,73]. The mutations do not limit the survival after allogenetic hematopoietic stem cell transplantation (HSCT),which means it influences negligibly the long term disease control of HSCT [74].…”

A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia

“…CLL is a biologically heterogeneous disease of the lymphoid system that is characterized by the progressive and irreversible growth of mature deficient B-cells and various genomic aberrations and mutations (Scupoli and Pizzolo, 2015). It is a disease of aged populations and the most common adult leukemia in the Western world, with an estimated incidence of 5.8 cases per 100,000 men per year and 3.0 per 100,000 women per year (Campregher and Hamerschlak, 2014;Strefford, 2015). It is estimated that there will be $14,620 new cases of CLL and $4650 deaths due to the disease in the United States alone in 2015 (Esencay and Hamad, 2015).…”

mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients

“…Chronic lymphocytic leukemia (CLL) constitutes a lymphoid malignancy with progressive accumulation of mature B-cells in the peripheral blood, bone marrow, liver, and lymphoid organs [1]. Diagnosis of CLL is based on a lymphocyte count ≥ 5 × 10 9 /L monoclonal B-cells in patients' peripheral blood for at least 3 months.…”